Foreign patients are increasingly traveling to China to receive medical treatment for serious health conditions [1].
This shift in medical tourism suggests a growing international confidence in Chinese healthcare infrastructure. As patients seek alternatives to expensive or unavailable treatments in their home countries, China is positioning itself as a competitive global hub for specialized care [1, 2].
Emma Holden, a citizen of New Zealand, traveled to Shanghai to seek treatment for myeloma [1, 2]. Her decision followed five years of attempted treatments in her home country [1, 2]. Holden represents a broader trend of foreign nationals seeking advanced medical interventions within the Chinese healthcare system [1].
Several factors contribute to the rise in medical tourism to cities like Shanghai. Lower treatment costs compared to Western nations make complex procedures more accessible [2]. Additionally, the Chinese government has implemented looser visa restrictions specifically for foreign patients, reducing the bureaucratic hurdles previously associated with entering the country for care [2].
Beyond cost and access, the international reputation of Chinese medical facilities is improving [1]. Hospitals in China, including those operated by groups like Raffles Medical, are actively attracting foreign patients by enhancing their service standards and specialized offerings [1].
Patients often arrive in China facing critical illnesses that require immediate or highly specialized attention. The availability of cutting-edge technology and a large volume of clinical cases allow Chinese hospitals to offer expertise that may be scarce elsewhere [1, 2].
“Foreign patients are increasingly traveling to China to receive medical treatment for serious health conditions.”
The rise of medical tourism in China indicates a strategic pivot by the Chinese government to monetize its healthcare sector and improve its global soft power. By lowering visa barriers and leveraging cost efficiencies, China is challenging the traditional dominance of the U.S. and Europe as primary destinations for high-end medical care, potentially altering the flow of global medical capital.
